Abstract
Background and Objective: The clinical manifestation of Parkinson’s disease (PD) is very heterogeneous, which inspired has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis in of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid 1-42 and index tau protein/beta-amyloid 1-42) and the clinical subtypes.
Methods: PD patients were divided into three subgroups - – early disease onset (EDO), tremor-dominant PD (TD-PD) and non-tremor dominant PD (NT-PD) according to the previously published classification. Neurodegenerative markers in the CSF were assessed in these three groups of patients suffering from PD (EDO-17, TD-15, NT-16 patients) and in a control group (CG) of 19 patients suffering from non-degenerative neurological diseases and 18 patients with Alzheimer\'s dementia (AD).
Results: The NT-PD patients were found to have significantly higher levels of CSF tau protein and index tau/beta than the control subjects and also than other Pparkinsonian subgroups, but not than AD patients.
Conclusion: In the context of more rapid clinical progression and more pronounced neuropathological changes in the NT-PD patient group, our results corroborate the opinion that CSF level of tau protein may be regarded as a potential laboratory marker of the presence and severity of neurodegeneration.
Keywords: Parkinson\'s disease subgroups, tau protein, beta-amyloid 1-42, index tau/beta, CSF
|
||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||
